The recent release of Librela (bedinvetmab), touted as a "miracle drug" for canine osteoarthritis, has deeply impacted thousands of pet owners and their beloved companions internationally since 2021. As a veterinary professional with over a decade of experience, I have witnessed the devastating consequences of this drug. Despite its promise of relief from arthritis pain, Librela has resulted in thousands of adverse reactions, leaving dogs in agony and their owners desperate for answers. It is imperative that action is taken to address this urgent issue.

The continued availability and promotion of Librela pose a grave threat to the well-being of countless dogs. With each passing day, more dogs are subjected to unnecessary suffering and even death as a result of severe adverse reactions to this drug. The lack of accountability from the manufacturer, Zoetis, exacerbates the problem, leaving pet owners with broken hearts, mounting medical bills, and unanswered questions. If left unchecked, the widespread use of Librela could lead to irreversible harm to countless canine companions and erode trust in the veterinary pharmaceutical industry and Zoetis.

Every moment that Librela remains on the market without further investigation and evaluation is a moment that puts more dogs at risk. Immediate action is needed to recall Librela and subject it to thorough testing to determine its safety and efficacy.

Zoetis has failed to provide crucial information on how long Librela lasts after injection, its complete metabolic process, and the management of adverse reactions, leaving pet owners and veterinarians in the dark. While some dogs may experience success with Librela, the thousands of dogs suffering from adverse reactions cannot be ignored. Zoetis should enhance the clarity of its product information regarding Librela, specifying suitable candidates for its use. This is particularly important given the drug's mechanism as a monoclonal antibody that targets the nerve growth factor (NGF). 

Together we must demand accountability from Zoetis and prioritize the health and well-being of our beloved canine companions.

If your dog has experienced side effects, please report to your country's regulator (e.g., FDA) and Zoetis, as thousands of veterinarians and owners already have (see www.adrreports.eu to search for the most comprehensive listing of reported adverse events).